Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare Drug Price Negotiation Program, delivering two more blows to the pharmaceutical industry this week after an appeals court upheld the dismissal of a similar case.

In Connecticut, the U.S. 2nd Circuit Court of Appeals upheld a decision granted by U.S. District Judge Michael P. Shea last year against pharmaceutical company Boehringer Ingelheim. The company's diabetes medication Jardiance was among the first 10 drugs chosen for Medicare negotiations, and two more of its products were chosen for the following round of negotiations.

In his 2024 ruling, Shea found that Boehringer Ingelheim could not demonstrate irreparable harm as a result of Medicare negotiations and also agreed with the federal government that the program did not........

© The Hill